Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Japan
  4. Japan Exchange
  5. Chugai Pharmaceutical Co., Ltd.
  6. News
  7. Summary
    4519   JP3519400000

CHUGAI PHARMACEUTICAL CO., LTD.

(4519)
  Report
End-of-day quote. End-of-day quote Japan Exchange - 10/22
3841 JPY   -0.93%
10/22PRESS RELEASE : FDA approves Roche's Susvimo, a -2-
DJ
10/22CHUGAI PHARMACEUTICAL : Organizational Changes
PU
10/22CHUGAI PHARMACEUTICAL : Announces 2021 3rd Quarter Results
PU
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Shares in Japan's Chugai surge on report of Roche buyout offer

08/18/2014 | 05:43am EDT

TOKYO (Reuters) - Shares in Japan's Chugai Pharmaceutical Co Ltd (>> CHUGAI PHARMACEUTICAL CO., LTD.) jumped 15 percent on Monday on a media report that its 60-percent shareholder, Roche Holding AG (>> Roche Holding Ltd.), was in talks to buy the rest of the company for about $10 billion (6 billion pounds).

TOKYO (Reuters) - Shares in Japan's Chugai Pharmaceutical Co Ltd (>> CHUGAI PHARMACEUTICAL CO., LTD.) jumped 15 percent on Monday on a media report that its 60-percent shareholder, Roche Holding AG (>> Roche Holding Ltd.), was in talks to buy the rest of the company for about $10 billion (6 billion pounds).

Chugai denied over the weekend that it was in talks with Roche over a buyout but investors dismissed the statement, sending the shares limit-up in early trade, to a record 4,015 yen, before closing up 15.4 percent at 3,825 yen.

"The market appears to believe the report but since it's not 100 percent certain, some took profit to send the shares off their high," said Mitsushige Akino, chief fund manager at Ichiyoshi Investment Management.

A source with direct knowledge of the matter said on Monday that Roche was not considering such a deal, citing price and saying both companies were happy with the current arrangement.

The reported $10 billion price tag would represent a premium of about 41 percent over Chugai's closing price on Friday.

European brokerage Kepler Cheuvreux said a $10 billion buyout of Chugai would be too expensive and "would hardly be exciting from a strategic perspective".

"We would be surprised if Roche was launching a hostile bid without trying to approach the Chugai board and attempting to find an amenable price for all," it said in a research note.

Bloomberg said the Swiss group could announce a deal to take full control of its Japanese partner for oncology and arthritis drugs as early as this week. A spokeswoman for Roche declined to comment on the report.

The source told Reuters that even at Friday's closing share price of 3,315 yen, which would value the remaining stake in Chugai at about 720 billion yen ($7 billion), an acquisition would be too expensive. The source declined to be identified because he was not authorised to speak to the media.

Speculation that Roche, the world's largest producer of cancer medicines, might swallow Chugai had swirled after Roche made a similar buyout of U.S. biotech group Genentech in 2009. But Roche and Chugai have made repeated denials.

Chugai's valuations - whether measured by price-to-earnings, price-to-book or price-to-cash flow - already exceed the median valuations of its Japanese peers, Thomson Reuters data shows.

Barclays said in a report that a $10 billion acquisition would be difficult to justify. Roche would retain an additional 200 million Swiss francs ($220 million) a year in shareholder payments, the investment bank said.

Analysts also said Roche may be looking to profit further from Chugai's drugs line-up and pipeline, including Actemra for rheumatism and ACE910 for haemophilia.

(Additional reporting by Chris Gallagher; Editing by Edmund Klamann and Mark Bendeich)

By Emi Emoto and Chang-Ran Kim

Stocks treated in this article : CHUGAI PHARMACEUTICAL CO., LTD., Roche Holding Ltd.

© Reuters 2014
Stocks mentioned in the article
ChangeLast1st jan.
CHUGAI PHARMACEUTICAL CO., LTD. -0.93% 3841 End-of-day quote.-30.20%
ROCHE HOLDING AG -0.56% 355.8 Delayed Quote.15.15%
US DOLLAR / JAPANESE YEN (USD/JPY) 0.02% 113.48 Delayed Quote.10.33%
All news about CHUGAI PHARMACEUTICAL CO., LTD.
10/22PRESS RELEASE : FDA approves Roche's Susvimo, a -2-
DJ
10/22CHUGAI PHARMACEUTICAL : Organizational Changes
PU
10/22CHUGAI PHARMACEUTICAL : Announces 2021 3rd Quarter Results
PU
10/22CHUGAI PHARMACEUTICAL : Notice of Revisions to Financial Forecasts
PU
10/22CHUGAI PHARMACEUTICAL : Notice of Revisions to Dividend Forecast for Fiscal Year Ending De..
PU
10/22CHUGAI PHARMACEUTICAL : Construction of New Bio API Plant for Early Clinical Trials to Acc..
PU
10/22CHUGAI PHARMACEUTICAL : 3Q Results (Jan-Sep 2021)
PU
10/22CHUGAI PHARMACEUTICAL : Supplementary Materials
PU
10/22CHUGAI PHARMACEUTICAL : CONSOLIDATED FINANCIAL STATEMENTS (IFRS) (Non-Audited)(for the thi..
PU
10/22CHUGAI PHARMACEUTICAL : Supplementary Materials for Consolidated Financial Results for the..
PU
More news
Analyst Recommendations on CHUGAI PHARMACEUTICAL CO., LTD.
More recommendations
Financials
Sales 2021 901 B 7 937 M 7 937 M
Net income 2021 274 B 2 411 M 2 411 M
Net cash 2021 438 B 3 860 M 3 860 M
P/E ratio 2021 23,1x
Yield 2021 1,56%
Capitalization 6 316 B 55 539 M 55 640 M
EV / Sales 2021 6,52x
EV / Sales 2022 6,49x
Nbr of Employees 7 555
Free-Float 37,8%
Chart CHUGAI PHARMACEUTICAL CO., LTD.
Duration : Period :
Chugai Pharmaceutical Co., Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CHUGAI PHARMACEUTICAL CO., LTD.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 13
Last Close Price 3 841,00 JPY
Average target price 4 696,92 JPY
Spread / Average Target 22,3%
EPS Revisions
Managers and Directors
Tatsuro Kosaka Chairman & Chief Executive Officer
Osamu Okuda President, COO & Representative Director
Itagaki Toshiaki CFO, Manager-Information Technology & Accounting
Hisafumi Okabe Senior Executive Officer & Head-Research
Junichi Nezu Executive Officer, GM-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
CHUGAI PHARMACEUTICAL CO., LTD.-30.20%55 539
JOHNSON & JOHNSON4.03%430 990
ROCHE HOLDING AG15.15%337 974
NOVO NORDISK A/S58.77%242 392
PFIZER, INC.16.44%241 985
ELI LILLY AND COMPANY44.37%220 979